TrialEuropean journal of cancer (Oxford, England : 1990)2013

A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas.

Jana Portnow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.